Science Can't Wait: A Discovery Series | Part 3 | Featuring Cancer Researcher Daniel Hollern

Why It Matters

Enhancing B‑cell activity could broaden immunotherapy effectiveness, offering breast‑cancer patients better survival odds and demonstrating the commercial value of basic, interdisciplinary research.

Key Takeaways

• CD40 agonist drug expands B cells, boosting breast cancer survival.
• B cells act as commanders, activating T‑cell anti‑tumor response.
• Single‑cell sequencing reveals tumor microenvironment changes after treatment.
• Removing B cells eliminates CD40 drug efficacy, confirming their essential role.
• Salk’s interdisciplinary model accelerates translation from basic discovery to therapies.

Summary

The Science Can’t Wait webinar’s third installment spotlighted Salk Institute researcher Daniel Hollern’s work on leveraging the immune system—specifically B cells—to combat breast cancer. The session framed the effort as part of a broader interdisciplinary push, where basic questions about cell transformation and plant resilience translate into tangible therapeutic strategies.

Hollern explained that a CD40 agonist drug dramatically expands a subset of B cells that act as “superheroes,” coordinating and sustaining T‑cell attacks on tumors. Single‑cell sequencing of treated versus untreated tumors showed a three‑fold rise in B‑cell numbers, a surge in T‑cell activity, and a marked reduction in cancer cells. In mouse models of aggressive triple‑negative breast cancer, the CD40 treatment extended overall survival and even cured a small fraction of tumors; this benefit vanished when B cells were depleted, underscoring their pivotal role.

Personal anecdotes reinforced the science: Hollern cited his grandfather’s fatal angiosarcoma and the missed immune response when lymph nodes were removed, prompting his focus on B‑cell‑driven immunity. He described B cells as “the commander of the army,” directing T‑cell “tanks” and delivering antibody‑like “heat‑seeking missiles” to tumor cells. Live‑cell imaging captured prolonged B‑T contacts after CD40 activation, while fluorescent markers revealed simultaneous receptor activation, visual proof of the proposed mechanism.

The findings suggest a new immunotherapy avenue that augments B‑cell function alongside existing T‑cell‑focused treatments, potentially raising response rates beyond the current 20‑30 % ceiling. By illustrating how foundational research at Salk can rapidly move toward clinical impact, the webinar also highlighted the institute’s collaborative model and its reliance on donor support to sustain such breakthroughs.

Original Description

Since January 2026, the Salk Institute has been partnering with the Del Mar Foundation on an exciting and informative webinar series, Science Can’t Wait: A Discovery Series. The three-part webinar series explores breakthroughs in brain health, cancer, Alzheimer’s disease, agricultural solutions, and more. Each session offers exclusive access to Salk scientists whose work is shaping the future of human health and our planet.

This special Science Can’t Wait webinar, “Turning the Immune System Against Breast Cancer,” features Salk cancer biologist Daniel Hollern, PhD, who talks about:

How our immune systems work and what cells are key to tackling cancer

Harnessing the power of our immune system’s B cells to fight cancer

Exciting treatment trials that are paving the way to tomorrow’s cancer treatments

What a future where cancer is entirely curable or preventable could look like

The Del Mar Foundation is offering a Challenge Match through July 31, 2026. Gifts from now until then will be matched 1:1, instantly doubling your support for groundbreaking research that directly affects our community and the world.

Donate now: https://www.salk.edu/science-cant-wait-a-discovery-series-registration/

Learn more about the Salk Institute: https://www.salk.edu/

Learn more about Daniel Hollern’s research: https://www.salk.edu/scientist/daniel-hollern/

#Cancer #CancerResearch #BreastCancer #BCell #Immunobiology #CancerBiology